Adherence to long-term anticoagulation treatment, what is known and what the future might hold

British Journal of Haematology

Volumn 174, Issue 1, 2016, Pages 30-42

  Abdou, John K ^a,b   Auyeung, Vivian ^a   Patel, Jignesh P ^a,b   Arya, Roopen ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

atrial fibrillation; direct oral anticoagulants; medication adherence; venous thromboembolism; vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGE; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HEALTH LITERACY; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; MENTAL FUNCTION; MOTIVATION; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SOCIAL STATUS; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 84976512811     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14134     Document Type: Review

References (91)

1. Abraham, I. & MacDonald, K. (2012) Why are patients with chronic myeloid leukaemia (non-) adherent? British Journal of Cancer, 107, 901–903.
2. Amin, A. & Marrs, J.C. (2015) Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clinical and Applied Thrombosis/Hemostasis, Epub ahead of print August 27, 2015, doi: 10.1177/1076029615601492
3. Arepally, G., Bauer, K.A., Bhatt, D.L., Merli, G.J., Naccarelli, G.V., Carter, R.D., Karcher, R.B., Berry, C.A., Keaton, K.L. & Stowell, S.A. (2010) The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Critical Pathways in Cardiology, 9, 41–48.
4. Arnsten, J.H., Gelfand, J.M. & Singer, D.E. (1997) Determinants of compliance with anticoagulation: a case-control study. The American Journal of Medicine, 103, 11–17.
5. Banerjee, S. (2014) Multimorbidity—older adults need health care that can count past one. The Lancet, 385, 587–589.
6. Beyer-Westendorf, J., Forster, K., Ebertz, F., Gelbricht, V., Michalski, F., Tittl, L. & Weiss, N. (2014) Drug persistence with rivaroxaban therapy in atrial fibrillation patients results from the dresden NOAC registry. Blood, 124, 4264–4264.
7. Borg Xuereb, C., Shaw, R.L. & Lane, D.A. (2012) Patientsɰ and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Education and Counseling, 88, 330–337.
8. Camm, A.J., Lip, G.Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S.H., Hindricks, G. & Kirchhof, P.; ESC Committee for Practice Guidelines (CPG). (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. developed with the special contribution of the european heart rhythm association. European Heart Journal, 33, 2719–2747.
9. Castellucci, L.A., Shaw, J., van der Salm, K., Erkens, P., Le Gal, G., Petrcich, W. & Carrier, M. (2015) Self-reported adherence to anticoagulation and its determinants using the morisky medication adherence scale. Thrombosis Research, 136, 727–731.
10. Chen, S.Y., Wu, N., Gulseth, M., LaMori, J., Bookhart, B.K., Boulanger, L., Fields, L. & Schein, J. (2013) One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. Journal of Managed Care Pharmacy, 19, 291–301.
11. Clarkesmith, D.E., Pattison, H.M., Lip, G.Y. & Lane, D.A. (2013a) Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE, 8, e74037.
12. Clarkesmith, D.E., Pattison, H.M. & Lane, D.A. (2013b) Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. The Cochrane Database of Systematic Reviews, 6, CD008600.
13. Clyne, W., Mshelia, C., McLachlan, S., Jones, P., de Geest, S., Ruppar, T., Siebens, K., Dobbels, F. & Kardas, P. (2016) A multinational cross-sectional survey of the management of patient medication adherence by european healthcare professionals. BMJ Open, 6, e009610-2015-009610.
14. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H., Joyner, C.D. & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139–1151.
15. Crivera, C., Nelson, W.W., Bookhart, B., Martin, S., Germain, G., Laliberte, F., Schein, J. & Lefebvre, P. (2015) Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Current Medical Research and Opinion, 31, 1889–1895.
16. Decker, C., Garavalia, L., Garavalia, B., Simon, T., Loeb, M., Spertus, J.A. & Daniel, W.C. (2012) Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. Journal of Multidisciplinary Healthcare, 5, 129–135.
17. Deitelzweig, S.B., Buysman, E., Pinsky, B., Lacey, M., Jing, Y., Wiederkehr, D. & Graham, J. (2013) Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clinical Therapeutics, 35, 1201–1210.
18. Di Minno, A., Spadarella, G., Tufano, A., Prisco, D. & Di Minno, G. (2014) Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thrombosis Research, 133, 699–704.
19. DiMatteo, M.R. (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care, 42, 200–209.
20. Eapen, Z.J., Mi, X., Qualls, L.G., Hammill, B.G., Fonarow, G.C., Turakhia, M.P., Heidenreich, P.A., Peterson, E.D., Curtis, L.H., Hernandez, A.F. & Al-Khatib, S.M. (2014) Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. Journal of Cardiac Failure, 20, 23–30.
21. Epstein, R.M. & Street, R.L. Jr (2011) The values and value of patient-centered care. Annals of Family Medicine, 9, 100–103.
22. Fang, M.C., Machtinger, E.L., Wang, F. & Schillinger, D. (2006) Health literacy and anticoagulation-related outcomes among patients taking warfarin. Journal of General Internal Medicine, 21, 841–846.
23. Forslund, T., Wettermark, B. & Hjemdahl, P. (2016) Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology, 72, 329–338.
24. Gadisseur, A.A., Breukink-Engbers, W.M., van der Meer, F.M., van den Besselaar, A.H., Sturk, A.A. & Rosendaal, F.R. (2003) Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the netherlands: a randomized clinical trial. Archives of Internal Medicine, 163, 2639–2646.
25. Gadisseur, A.P., Kaptein, A.A., Breukink-Engbers, W.G., van der Meer, F.J. & Rosendaal, F.R. (2004) Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. Journal of Thrombosis and Haemostasis: JTH, 2, 584–591.
26. Gage, B.F., van Walraven, C., Pearce, L., Hart, R.G., Koudstaal, P.J., Boode, B.S. & Petersen, P. (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation, 110, 2287–2292.
27. Gladstone, D.J., Geerts, W.H., Douketis, J., Ivers, N., Healey, J.S. & Leblanc, K. (2015) How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by thrombosis canada, the canadian stroke consortium, the canadian cardiovascular pharmacists network, and the canadian cardiovascular society. Annals of Internal Medicine, 163, 382–385.
28. Gomes, T., Mamdani, M.M., Holbrook, A.M., Paterson, J.M. & Juurlink, D.N. (2012) Persistence with therapy among patients treated with warfarin for atrial fibrillation. Archives of Internal Medicine, 172, 1687–1689.
29. Gorst-Rasmussen, A., Skjoth, F., Larsen, T.B., Rasmussen, L.H., Lip, G.Y. & Lane, D.A. (2015) Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. Journal of Thrombosis and Haemostasis: JTH, 13, 495–504.
30. Granger, C.B., Alexander, J.H., McMurray, J.J.V., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B.J., Golitsyn, S., Goto, S., Hermosillo, A.G., Hohnloser, S.H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B.S., Lopez-Sendon, J., Pais, P., Parkhomenko, A., Verheugt, F.W.A., Zhu, J. & Wallentin, L. (2011) Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365, 981–992.
31. Gumbinger, C., Holstein, T., Stock, C., Rizos, T., Horstmann, S. & Veltkamp, R. (2015) Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. European Neurology, 73, 184–191.
32. Hanemaaijer, S., Sodihardjo, F., Horikx, A., Wensing, M., De Smet, P.A., Bouvy, M.L. & Teichert, M. (2015) Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the netherlands. International Journal of Clinical Pharmacy, 37, 1128–1135.
33. Harper, P.L., Fong, S.C. & Chen, L. (2015) Dabigatran persistence and adherence in new zealand. Journal of Thrombosis and Haemostasis, 13, 36–36.
34. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A.J. & Kirchhof, P.; Advisors. (2015) Updated european heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 17, 1467–1507.
35. Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J. & Deykin, D. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 119, 8S–21S.
36. Horne, R., Weinman, J., Barber, N., Elliot, R. & Morgan, M. (2005) Concordance, adherence and compliance in medicine taking. Report for the national co-ordinating centre for NHS service delivery and organisation R & D (NCCSDO). Available at http://www.nets.nihr.ac.uk/projects/hsdr/081412076
37. Hu, Y.F., Liao, J.N., Chern, C.M., Weng, C.H., Lin, Y.J., Chang, S.L., Wu, C.H., Sung, S.H., Wang, K.L., Lu, T.M., Chao, T.F., Lo, L.W., Chung, F.P., Hsu, L.C. & Chen, S.A. (2015) Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor. Pacing and Clinical Electrophysiology: PACE, 38, 465–471.
38. Ingelgard, A., Hollowell, J., Reddy, P., Gold, K., Tran, K. & Fitzmaurice, D. (2006) What are the barriers to warfarin use in atrial fibrillation?: development of a questionnaire. Journal of Thrombosis and Thrombolysis, 21, 257–265.
39. Jackson, C., Eliasson, L., Barber, N. & Weinman, J. (2014) Applying COM-B to medication adherence: a suggested framework for research and interventions. The European Health Psychologist, 16, 7–17.
40. Kimmel, S.E., Chen, Z., Price, M., Parker, C.S., Metlay, J.P., Christie, J.D., Brensinger, C.M., Newcomb, C.W., Samaha, F.F. & Gross, R. (2007) The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (in-range) study. Archives of Internal Medicine, 167, 229–235.
41. Kimmel, S.E., Troxel, A.B., Loewenstein, G., Brensinger, C.M., Jaskowiak, J., Doshi, J.A., Laskin, M. & Volpp, K. (2012) Randomized trial of lottery-based incentives to improve warfarin adherence. American Heart Journal, 164, 268–274.
42. Krueger, K.P., Berger, B.A. & Felkey, B. (2005) Medication adherence and persistence: a comprehensive review. Advances in Therapy, 22, 313–356.
43. Laliberte, F., Nelson, W.W., Lefebvre, P., Schein, J.R., Rondeau-Leclaire, J. & Duh, M.S. (2012) Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Advances in Therapy, 29, 675–690.
44. Laliberte, F., Cloutier, M., Nelson, W.W., Coleman, C.I., Pilon, D., Olson, W.H., Damaraju, C.V., Schein, J.R. & Lefebvre, P. (2014) Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current Medical Research and Opinion, 30, 1317–1325.
45. Lane, D.A., Langman, C.M., Lip, G.Y. & Nouwen, A. (2009) Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. Journal of Psychosomatic Research, 66, 203–210.
46. Lip, G.Y., Kamath, S., Jafri, M., Mohammed, A. & Bareford, D. (2002) Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the west birmingham atrial fibrillation project. Stroke; a Journal of Cerebral Circulation, 33, 238–242.
47. Macedo, A.F., Bell, J., McCarron, C., Conroy, R., Richardson, J., Scowcroft, A., Sunderland, T. & Rotheram, N. (2015) Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink. Thrombosis Research, 136, 250–260.
48. Man-Son-Hing, M., Laupacis, A., O'Connor, A.M., Biggs, J., Drake, E., Yetisir, E. & Hart, R.G. (1999) A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA, 282, 737–743.
49. Martinez, C., Katholing, A., Wallenhorst, C. & Freedman, S.B. (2015) Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thrombosis and Haemostasis, 115, 31–39.
50. McAlister, F.A., Man-Son-Hing, M., Straus, S.E., Ghali, W.A., Anderson, D., Majumdar, S.R., Gibson, P., Cox, J.L. & Fradette, M.; Decision Aid in Atrial Fibrillation (DAAFI) Investigators. (2005) Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ: Canadian Medical Association Journal, 173, 496–501.
51. McCabe, P.J. & Barnason, S.A. (2012) Illness perceptions, coping strategies, and symptoms contribute to psychological distress in patients with recurrent symptomatic atrial fibrillation. Journal of Cardiovascular Nursing, 27, 431–444.
52. McCabe, P.J., Barnason, S.A. & Houfek, J. (2011) Illness beliefs in patients with recurrent symptomatic atrial fibrillation. Pacing & Clinical Electrophysiology, 34, 810–820.
53. Michie, S., van Stralen, M.M. & West, R. (2011) The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implementation Science, 6, 42-5908-6-42.
54. Montalescot, G. (2015) Assessment of an education and guidance program for apixaban adherence in non-valvular atrial fibrillation: The randomized AEGEAN study. European Society of Cardiology, London Congress 2015, ESC Congress 2015, Abstract 2191.
55. Naderi, S.H., Bestwick, J.P. & Wald, D.S. (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The American Journal of Medicine, 125, e1.
56. National Patient Safety Agency. (2007) Actions that can make anticoagulant therapy safer - patient safety alert 18. NPSA/2007/18-0440. http://www.nrls.npsa.nhs.uk/resources/?EntryId45=59814.
57. Nelson, W.W., Song, X., Thomson, E., Smith, D.M., Coleman, C.I., Damaraju, C.V. & Schein, J.R. (2015) Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Current Medical Research and Opinion, 31, 1831–1840.
58. Nerini, E., Grip, L., Camm, A.J. & Giugliano, R.P. (2013) Atrial fibrillation and the ‘other drug problem’: reducing non-adherence with technology. European Heart Journal, 34, 2031–2033.
59. NICE. (2009) Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. NICE Guideline CG76. National Institute for Health and Clinical Excellence, London, UK. https://www.nice.org.uk/guidance/cg76.
60. NICE. (2012) Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing. NICE Guideline CG 144. National Institute for Health and Clinical Excellence, London, UK. https://www.nice.org.uk/guidance/cg144
61. NICE. (2014) Atrial Fibrillation: Management. NICE Guideline CG 180. National Institute for Health and Clinical Excellence, London, UK. https://www.nice.org.uk/guidance/cg180
62. O'Carroll, R., Whittaker, J., Hamilton, B., Johnston, M., Sudlow, C. & Dennis, M. (2011) Predictors of adherence to secondary preventive medication in stroke patients. Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine, 41, 383–390.
63. Orensky, I.A. & Holdford, D.A. (2005) Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy, 25, 1801–1808.
64. Osterberg, L. & Blaschke, T. (2005) Adherence to medication. New England Journal of Medicine, 353, 487–497.
65. Parker, C.S., Chen, Z., Price, M., Gross, R., Metlay, J.P., Christie, J.D., Brensinger, C.M., Newcomb, C.W., Samaha, F.F. & Kimmel, S.E. (2007) Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. Journal of General Internal Medicine, 22, 1254–1259.
66. Platt, A.B., Localio, A.R., Brensinger, C.M., Cruess, D.G., Christie, J.D., Gross, R., Parker, C.S., Price, M., Metlay, J.P., Cohen, A., Newcomb, C.W., Strom, B.L., Laskin, M.S. & Kimmel, S.E. (2008) Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiology & Drug Safety, 17, 853–860.
67. Rose, A.J., Miller, D.R., Ozonoff, A., Berlowitz, D.R., Ash, A.S., Zhao, S., Reisman, J.I. & Hylek, E.M. (2013) Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest, 143, 751–757.
68. Ross, S., Walker, A. & MacLeod, M.J. (2004) Patient compliance in hypertension: role of illness perceptions and treatment beliefs. Journal of Human Hypertension, 18, 607–613.
69. Rubboli, A. (2015) Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Current Medical Research and Opinion, 31, 1845–1847.
70. Ryan, R., Santesso, N., Lowe, D., Hill, S., Grimshaw, J., Prictor, M., Kaufman, C., Cowie, G. & Taylor, M. (2014) Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. The Cochrane Database of Systematic Reviews, 4, CD007768.
71. Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J. & Goldhaber, S.Z. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine, 361, 2342–2352.
72. Schulman, S., Kearon, C., Kakkar, A.K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A.M., Friedman, J., Mismetti, P. & Goldhaber, S.Z. (2013a) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine, 368, 709–718.
73. Schulman, S., Shortt, B., Robinson, M. & Eikelboom, J.W. (2013b) Adherence to anticoagulant treatment with dabigatran in a real-world setting. Journal of Thrombosis and Haemostasis, 11, 1295–1299.
74. Shore, S., Carey, E.P., Turakhia, M.P., Jackevicius, C.A., Cunningham, F., Pilote, L., Bradley, S.M., Maddox, T.M., Grunwald, G.K., Baron, A.E., Rumsfeld, J.S., Varosy, P.D., Schneider, P.M., Marzec, L.N. & Ho, P.M. (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. American Heart Journal, 167, 810–817.
75. Shore, S., Ho, P., Lambert-Kerzner, A., Glorioso, T.J., Carey, E.P., Cunningham, F., Longo, L., Jackevicius, C., Rose, A. & Turakhia, M.P. (2015) Site-level variation in and practices associated with dabigatran adherence. JAMA, 313, 1443–1450.
76. Siegal, D.M., Curnutte, J.T., Connolly, S.J., Lu, G., Conley, P.B., Wiens, B.L., Mathur, V.S., Castillo, J., Bronson, M.D., Leeds, J.M., Mar, F.A., Gold, A. & Crowther, M.A. (2015) Andexanet alfa for the reversal of factor xa inhibitor activity. New England Journal of Medicine, 373, 2413–2424.
77. Simon, J., Hawes, E., Deyo, Z. & Bryant Shilliday, B. (2015) Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. Journal of Clinical Pharmacy and Therapeutics, 40, 525–530.
78. Simons, L.A., Ortiz, M., Germanos, P. & Calcino, G. (2013) Persistence on warfarin in patients with atrial fibrillation: experience in australia 2006–2009. Australian Family Physician, 42, 659–661.
79. Sjolander, M., Eriksson, M. & Glader, E.L. (2013) The association between patients' beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open, 3, e003551-2013-003551.
80. Suryanarayan, D., Al-Khalili, F., Majeed, A. & Schulman, S. (2015) Dabigatran and rivaroxaban adherence study- real world experience in different clinics and extended follow up (dariva study). Journal of Thrombosis and Haemostasis, 13, 636–636.
81. Ten Cate, H. (2013) New oral anticoagulants: discussion on monitoring and adherence should start now! Thrombosis Journal, 11, 8-9560-11-8.
82. Thorne, K., Jayathissa, S., Dee, S., Briggs, N., Taylor, J., Reid, S., De Silva, K. & Dean, J. (2014) Adherence and outcomes of patients prescribed dabigatran (pradaxa) in routine clinical practice. Internal Medicine Journal, 44, 261–265.
83. Vrijens, B. & Heidbuchel, H. (2015) Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace: European Pacing Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 17, 514–523.
84. Vrijens, B., De Geest, S., Hughes, D.A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J.K. & Urquhart, J.; for the ABC Project Team. (2012) A new taxonomy for describing and defining adherence to medications. British Journal of Clinical Pharmacology, 73, 691–705.
85. Walsh, K.E., Cutrona, S.L., Kavanagh, P.L., Crosby, L.E., Malone, C., Lobner, K. & Bundy, D.G. (2014) Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics, 134, 1175–1183.
86. Wang, Y., Kong, M.C., Lee, L.H., Ng, H.J. & Ko, Y. (2014) Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thrombosis Research, 133, 550–554.
87. Wild, D., Murray, M. & Donatti, C. (2009) Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Review of Pharmacoeconomics & Outcomes Research, 9, 467–474.
88. World Health Organization. (2003) Adherence to long-term therapies: Evidence for action. http://www.who.int/chp/knowledge/publications/adherence_report/en/.
89. Yao, X., Abraham, N.S., Alexander, G.C., Crown, W., Montori, V.M., Sangaralingham, L.R., Gersh, B.J., Shah, N.D. & Noseworthy, P.A. (2016) Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. Journal of the American Heart Association, 5, doi: 10.1161/JAHA.115.003074
90. Zalesak, M., Siu, K., Francis, K., Yu, C., Alvrtsyan, H., Rao, Y., Walker, D., Sander, S., Miyasato, G., Matchar, D. & Sanchez, H. (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circulation. Cardiovascular Quality and Outcomes, 6, 567–574.
91. Zhou, M., Chang, H.Y., Segal, J.B., Alexander, G.C. & Singh, S. (2015) Adherence to a novel oral anticoagulant among patients with atrial fibrillation. Journal of Managed Care & Specialty Pharmacy, 21, 1054–1062.